Visual inspection in the first step of our investigation, we performed a visual inspection of the product.We have checked for possible damages, deformations of the housing or other abnormalities.The following observations were made during the visual inspection: no defects or other abnormalities are detected.Permeability test.To check if the m.Blue plus® is blocked, we have performed a permeability test on the shunt system.This test is carried out with the product in the horizontal position with a hydrostatic pressure difference of approx.30 cmh2o in the direction of flow.The test showed that the m.Blue plus® shunt system is permeable.Adjustability test.We have investigated whether the m.Blue and progav 2.0 can be successfully set to each specified pressure setting.Thus indicating whether the valves are fully adjustable within the full range of specified pressure settings (in increments of 4 cmh2o (m.Blue) and in increments of 5 cmh2o (progav 2.0) ).The m.Blue® and the progav® 2.0 were found to be adjustable to all pressure settings.Braking force and brake function test.The braking force and brake function test investigates whether the braking function of the adjustable valves is present and how much force must be exerted on the housing to release the rotor to adjust the valves using the integrated magnet of a specific measurement apparatus of braking force.The braking force of the both valves were within the specified tolerance and the brake function operated as expected.Internal inspection of product.In order to verify whether the investigated shunt system was compromised by the known risks of hydrocephalus therapy, e.G.By a build-up of natural substances (protein, blood, or tissue particles) in the cerebrospinal fluid, we have dismantled the shunt system.After dismantling of the valves, clearly deposits were found in both valves.Results.Based on our investigation, we are not able to substantiate the claim of "non- adjustability".However, we assume that the significant deposits found within the valve may have temporarily caused the functional impairment.Deposits caused by natural substances in the cerebrospinal fluid, such as protein, blood or tissue particles, are among the known and unavoidable risks and side effects of hydrocephalus therapy.We can exclude a defect at the time of release.The shunt system met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.
|